Table 1 Patient demographics and baseline characteristics, overall and by phase of depression
From: Emotional blunting in patients with depression. Part I: clinical characteristics
All patients (N = 752) | Acute (n = 300) | Remission (n = 452) | |
|---|---|---|---|
Sex, n (%) | |||
Female | 466 (62)a | 195 (65)a | 271 (60)a |
Age, years | |||
Mean (SD) | 45 (12) | 46 (12) | 47 (13) |
Time since diagnosis of depression (months) | |||
Mean (SD) | 62.4 (49.5) | 61.3 (48.3) | 63.2 (50.3) |
High school education or above, n (%) | 596 (79) | 235 (78) | 361 (80) |
Work status, n (%) | |||
Full-time | 348 (46) | 120 (40) | 228 (50)** |
Part-time | 93 (12) | 33 (11) | 60 (13) |
In a relationship, n (%) | 471 (63) | 181 (60) | 290 (64) |
Ever addicted to drugs or alcohol, n (%) | 156 (21) | 71 (24) | 85 (19) |
Any severe trauma, n (%) | 658 (88) | 276 (92)** | 382 (85) |
Current treatment used for depression, n (%)b | |||
Fluoxetine | 199 (26) | 87 (29) | 112 (25) |
Escitalopram | 125 (17) | 52 (17) | 73 (16) |
Sertraline | 121 (16) | 53 (18) | 68 (15) |
Citalopram | 110 (15) | 48 (16) | 62 (14) |
Venlafaxine | 100 (13) | 46 (15) | 54 (12) |
Bupropion | 79 (11) | 46 (15)** | 33 (7) |
Paroxetine | 78 (10) | 32 (11) | 46 (10) |
Duloxetine | 56 (7) | 26 (9) | 30 (7) |
Mirtazapine | 44 (6) | 18 (6) | 26 (6) |
Desvenlafaxine | 34 (5) | 16 (5) | 18 (4) |
Vortioxetine | 27 (4) | 13 (4) | 14 (3) |
Agomelatine | 26 (3) | 15 (5) | 11 (2) |
Other drug therapy | 176 (23) | 84 (28)* | 92 (20) |
Unsure/don’t know | 14 (2) | 5 (2) | 9 (2) |